Rama Krishna Sangem
More and more heart patients in India are now using Novartis company’s Inclisiran injection, that costs Rs 1.28 lakh, of 1.25 ml. Patients as well as those who suspect possible heart diseases too are preferring this in India This is a package of 6 injections, each goes with gap of 6 months – for a 3 year period. This injection is meant to check bad cholesterol in blood, and avoid a possible heart attack. Not surprisingly, Inclisiran sales in India have doubled in the last one year.
In 2025, the Indian market for inclisiran, a cholesterol-lowering drug, is expected to see growth. While specific sales figures for the year are not available, the market is predicted to reach USD 607.34 Million by 2033, exhibiting a growth rate of 3.96% between 2025 and 2033. Novartis, the manufacturer of inclisiran (also sold as Leqvio and Sybrava in different markets), has implemented a financing scheme and is partnering with Indian firms to expand its reach.
Novartis launched a zero-interest EMI plan to make the drug more accessible to patients. People are buying on EMIs shows its popularity and the way doctors recommending it. Excel India found it out from Hyderabad’s medical shops and heart specialists that regular heart diseases patients are placing orders for inclisiran, while continuing other medicines. “We take at least a week to get this injection,” said a medical shop owner in Basheerbagh in Hyderabad.
Sure fight against cholesterol
Reasons for increased sales: The increasing number of individuals with high cholesterol and dyslipidemia is a major driver for the demand of cholesterol-lowering drugs like inclisiran.
Latest trend to fight treat cholesterol: Inclisiran offers an alternative to traditional statins, particularly for patients who are statin-intolerant or whose cholesterol levels are not adequately controlled by statins. Novartis’s Strategies: Novartis’s financing schemes and partnerships with Indian pharmaceutical firms aim to expand market access and drive sales.
Accessibility through Financing: The zero-interest EMI plan offered by Novartis makes the expensive drug more affordable for a wider range of patients. Increased Awareness: Growing awareness about the importance of cholesterol management and the benefits of inclisiran is also expected to contribute to sales.
Specific Sales Figures and Market Size: Global sales of inclisiran (Leqvio) were estimated at $354 million in 2023 and are projected to reach $3 billion by 2029. The India antihyperlipidemic drugs market reached USD 428.19 Million in 2024. PharmaTrac data shows that inclisiran sales reached ₹7.7 crore in the year following April 2024, indicating the drug’s growing popularity and market presence.
